Sumatriptan

Sumatriptan
(IUPAC) ime
	1-[3-(2-dimetilaminoetil)-1H-indol-5-il]- N-metil-metanesulfonamid
Klinički podaci
Robne marke	Imitrex
AHFS/Drugs.com	Monografija
Identifikatori
CAS broj	103628-46-2
ATC kod	N02CC01
PubChem	5358
DrugBank	APRD00379
ChemSpider	5165
UNII	8R78F6L9VO
KEGG	D00451
ChEBI	CHEBI:10650
ChEMBL	CHEMBL128
Hemijski podaci
Formula	C14H21N3O2S
Mol. masa	295.402 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3 ; Key: KQKPFRSPSRPDEB-UHFFFAOYSA-N
Farmakokinetički podaci
Bioraspoloživost	15% (oralno)/ 96% (s.c)
Vezivanje za proteine plazme	14%-21%
Metabolizam	MAO
Poluvreme eliminacije	2.5 časa
Izlučivanje	60% urin; 40% izmet
Farmakoinformacioni podaci
Licenca	US FDA:link
Trudnoća	?
Pravni status
Način primene	tablet, subcutaneous injection, nasal spray

Sumatriptan je triptan sulfonamidni lek koji sadrži sulfonamidnu grupu. On se koristi za lečenje migrenskih glavobolja.^[6] Sumatriptan proizvode i prodaju brojni proizvođači lekova pod mnoštvom imena, kao što su: Sumatriptan, Imitreks, i Imigran.^[7]

Odobrenje i dostupnost uredi

Sumatriptan je 1991. bio privi klinički dostupni triptan. U SAD-u i većini razvijenih zemalja, on je dostupan samo uz lekarsku proskripciju. On se može kupiti na slobodno u UK-u u dozi od 50 mg, ako je ranije bio propisan pacijentu. On se prodaje u nekoliko formi: tablete, rastvor za injekcije, i nazalni inhaler.

FDA je 2008. odobrio upotrebu kombinacije sumatriptana i naproksena.^[8] Pokazano je da taj lek ima više prednosti u odnosu na bilo koju od njegovih komponenti.^[9]

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
↑ Tepper S. J., Rapoport A. M. (1999). „The triptans - A summary”. CNS Drugs 12 (5): 403–417. DOI:10.2165/00023210-199912050-00007.
↑ „GSK press release - Treximet (sumatriptan and naproxen sodium) tablets approved by FDA for acute treatment of migraine”. Arhivirano iz originala na datum 2008-12-04. Pristupljeno 2014-04-05.
↑ Brandes JL, Kudrow D, Stark SR, et al. (April 2007). „Sumatriptan-naproxen for acute treatment of migraine: a randomized trial”. JAMA 297 (13): 1443–54. DOI:10.1001/jama.297.13.1443. PMID 17405970.

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[Goodman_Gilman-6] Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.

[7] Tepper S. J., Rapoport A. M. (1999). „The triptans - A summary”. CNS Drugs 12 (5): 403–417. DOI:10.2165/00023210-199912050-00007.

[8] „GSK press release - Treximet (sumatriptan and naproxen sodium) tablets approved by FDA for acute treatment of migraine”. Arhivirano iz originala na datum 2008-12-04. Pristupljeno 2014-04-05.

[pmid17405970-9] Brandes JL, Kudrow D, Stark SR, et al. (April 2007). „Sumatriptan-naproxen for acute treatment of migraine: a randomized trial”. JAMA 297 (13): 1443–54. DOI:10.1001/jama.297.13.1443. PMID 17405970.

[6]

[7]

[1]

[2]

[3]

[4]

[5]

[8]

[9]